Project Grant R41GM123858

The National Institute of General Medical Sciences (NIGMS) awarded a $350,000 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Medosome Biotec LLC, a for-profit limited liability company. The grant, awarded on September 12, 2024, will support research and development to evaluate the safety and therapeutic potential of dichloroacetate (DCA) as a treatment for sepsis. Medosome Biotec will collaborate with researchers at the University of Florida, Wake...

This $305,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a clinical decision support system (CDSS) called Sepsis FLO. The CDSS is designed to precisely guide blood volume diagnosis and treatment for sepsis patients. Key activities include: 1) Developing an alpha prototype of the CDSS through user-centered design; 2) Validating three functional...

This $356,500 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of chemically modified DNA aptamers for improved sepsis diagnosis. The grantee, Aptus Biosciences LLC, is a minority-owned small business specializing in advanced diagnostic research and development, with a focus on innovative aptamer-based technologies. The project aims to create rapid, affordable,...

This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....

This Project Grant award for $684,206, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a nanoparticle-based immunotherapy to address the complex immune dysregulation associated with sepsis. The funds will support research to advance the development of "immunomodulatory nanoparticles" (INPs) - a drug-free class of poly(lactic acid)-based nanoparticles designed to...

This Project Grant award of $750,561 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the SMART-SEPSIS study. The study aims to use electronic health record data and artificial intelligence/machine learning to model individual patient response to sepsis treatment and promote early but reasoned application of the hour-1 sepsis treatment bundle for patients with suspected community-onset lung sepsis. The goal is...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $473,937 Project Grant to The General Hospital Corporation (d/b/a Massachusetts General Hospital) for the project "Novel Point-of-Care Liquid Biopsy for Early Detection of Sepsis-Associated Organ Damage". The project aims to develop a novel circulating cellular biomarker for the early detection and assessment of...

The federal Project Grant award of $783,661.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a pragmatic, randomized clinical trial to evaluate the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study, conducted by the Mayo Clinic, aims to provide an alternative to intravenous vasopressors and reduce the burden of intensive care unit (ICU) stays for these...

This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Temple University provides $683,299 to conduct research on the functional immune phenotypes of sepsis patients. The project aims to integrate microphysiological assays, omics data, and in silico modeling to better understand how different neutrophil subpopulations and their interactions with the vascular endothelium contribute to sepsis-induced organ dysfunction....

This federal Project Grant award of $423,500.00, provided by the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program, aims to address two critical challenges related to burn sepsis: Identifying distinct immune response phenotypes after burn injury and their relation to sepsis development, in order to enable novel approaches to mitigate sepsis risk. Determining the mechanism by which elevated angiopoietin-2 (ANGPT-2) leads...